Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation
详细信息 查看全文
- 作者：Gary J. Schiller1 ; gschiller@mednet.ucla.edu" class="auth_mail" title="E-mail the corresponding author ; Pamela Tuttle2 ; Pinkal Desai3
- 关键词：Acute myelogenous leukemia ; Allogeneic hematopoietic stem cell transplantation ; FLT3 ; FLT3-ITD ; Tyrosine kinase inhibitor
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：22
- 期：6
- 页码：982-990
- 全文大小：437 K
文摘
- •
With recent advances, allo-HSCT improves survival in patients with AML.
- •
FLT3-ITD mutations are associated with poor prognosis, even after transplantation.
- •
FLT3 inhibitors have been studied in patients with FLT3 mutations (eg, FLT3-ITD).
- •
In these patients, FLT3 inhibition after allo-HSCT may improve long-term outcomes.
- •
30">Studies testing this hypothesis are underway.